Care Access - Thousand Oaks

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Obesity5 trials
• Type 2 diabetes4 trials
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Heart failure1 trial
• Osteoarthritis1 trial
• Peripheral artery disease1 trial
• Stroke1 trial
• Type 1 diabetes1 trial

Phase

• Phase 35 trials

Status

• Active, not recruiting5 trials

Lead sponsor

• Eli Lilly and Company5 trials

Running trials

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

  NCT07153471· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT06972472· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

  NCT06993792· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

  NCT06972459· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source